UK Markets close in 6 hrs 43 mins

Hikma Pharmaceuticals PLC (HIK.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,384.00-35.00 (-2.47%)
As of 9:28AM BST. Market open.
People also watch
SHP.LAHT.LBAB.LHL.LITRK.L
Full screen
Previous close1,419.00
Open1,419.00
Bid1,381.00 x 16300
Ask1,383.00 x 34600
Day's range1,383.00 - 1,419.00
52-week range1,339.50 - 2,703.00
Volume39,137
Avg. volume768,168
Market cap3.33B
Beta0.13
PE ratio (TTM)20.91
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield0.44 (2.38%)
Ex-dividend date2017-04-06
1y target estN/A
  • TheStreet.com28 days ago

    Hikma Shakes Up U.S. Operations After FDA Disappointment; CEO Said Darwazah to Lead Group

    Hikma shares were active in London trading Monday after the drugmaker unveiled a reorganization of its U.S. business that includes a change in leadership.

  • Reuters - UK Focus2 months ago

    FTSE climbs for fourth straight week, shrugging off Trump slump

    The FTSE 100 was up nearly 0.5 percent on the day, bringing it into positive territory for the week after its performance was dented by worries over turmoil in U.S. President Donald Trump's administration that sent stocks tumbling across the globe. Investors looked through the political uncertainty to a better earnings season and improved UK retail sales data which pointed to a brighter outlook for consumer-facing stocks.

  • Reuters2 months ago

    Hikma cuts revenue forecast on generic Advair delay; shares sink

    Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low. Earlier this month, the drugmaker said U.S. regulators decided not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application. The company, which makes and markets branded and non-branded generic and injectable drugs, now expects full-year revenue to be in the range of $2 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion.